Senl-1904B

N/A

Report date: 2026/03/04 20:01:44

Base Information

Drug NameSenl-1904B
Drug Alias NameAnti CD19 chimeric antigen receptor T-cell therapy Senl_1904B - Hebei Senlang Biotechnology1904B CAR-TAnti CD19 chimeric antigen receptor T-cell therapy Senl_1904BAutologous CD19-targeting CAR T cell therapyCD19 CAR-T +[9] 
ClassificationCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionImmunologic cytotoxicityT lymphocyte replacementsB-lymphocyte antigen CD19 modulators
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsColitis, UlcerativePrecursor B-Cell Lymphoblastic Leukemia-LymphomaPrecursor Cell Lymphoblastic Leukemia-Lymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesHebei Senlang Biological Technology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesHebei Senlang Biological Technology Co Ltd
Inactive CompaniesN/A
Active IndicationsColitis, UlcerativePrecursor B-Cell Lymphoblastic Leukemia-Lymphoma
Inactive IndicationsPrecursor Cell Lymphoblastic Leukemia-Lymphoma

Other Information

ATC CodeN/A
Related LinksN/A